Therapeutic implications of endothelin and thrombin G-protein-coupled receptor transactivation of tyrosine and serine/threonine kinase cell surface receptors

Journal of Pharmacy and Pharmacology

Volumn 65, Issue 4, 2013, Pages 465-473

  Kamato, Danielle ^a   Burch, Micah L ^a,b   Osman, Narin ^a   Zheng, Wenhua ^c   Little, Peter J ^a,b  

^a RMIT UNIVERSITY   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

GPCR; protein serine threonine kinases; protein tyrosine kinases; transactivation

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; BOSENTAN; CELL SURFACE PROTEIN; CELL SURFACE RECEPTOR; CYCLIC AMP; ENDOTHELIN; EPIDERMAL GROWTH FACTOR RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLYCOSAMINOGLYCAN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; GUANOSINE TRIPHOSPHATE; JANUS KINASE; LIPID; PHOSPHATIDYLINOSITIDE; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 4 PHOSPHATE; PHOSPHOLIPASE C; PLECKSTRIN; PROTEIN SERINE THREONINE KINASE; PROTEOGLYCAN; RAC PROTEIN; RAS PROTEIN; RHO FACTOR; RHO KINASE; STAT PROTEIN; THROMBIN; TRANSFORMING GROWTH FACTOR BETA; TYROSINE KINASE RECEPTOR; UNINDEXED DRUG;

ATHEROSCLEROSIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG TARGETING; HUMAN; IN VITRO STUDY; PROTEOGLYCAN SYNTHESIS; REVIEW; TRANSACTIVATION; TREATMENT RESPONSE; VASCULAR SMOOTH MUSCLE;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; DRUG DESIGN; ENDOTHELINS; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR-INTERACTING PROTEIN SERINE-THREONINE KINASES; RECEPTORS, CELL SURFACE; RECEPTORS, ENDOTHELIN; RECEPTORS, THROMBIN; SIGNAL TRANSDUCTION; THROMBIN;

EID: 84875270385     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01577.x     Document Type: Review

References (75)

1. George SR, et al,. G-protein-coupled receptor oligomerization and its potential for drug discovery. Nat Rev Drug Discov 2002; 1: 808-820.
2. Soh UJ, et al,. Signal transduction by protease-activated receptors. Br J Pharmacol 2010; 160: 191-203.
3. Lefkowitz RJ,. Seven transmembrane receptors: something old, something new. Acta Physiol (Oxf) 2007; 190: 9-19.
4. Blume-Jensen P, Hunter T,. Oncogenic kinase signalling. Nature 2001; 411: 355-365.
5. Waters C, et al,. The role of G-protein coupled receptors and associated proteins in receptor tyrosine kinase signal transduction. Semin Cell Dev Biol 2004; 15: 309-323.
6. Wharton K, Derynck R,. TGFbeta family signaling: novel insights in development and disease. Development 2009; 136: 3691-3697.
7. Heldin CH,. Development and possible clinical use of antagonists for PDGF and TGF-beta. Ups J Med Sci 2004; 109: 165-178.
8. Capdeville R, et al,. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002; 1: 493-502.
9. Bokoch MP, et al,. Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature 2010; 463: 108-112.
10. Gutkind JS,. Cell growth control by G protein-coupled receptors: from signal transduction to signal integration. Oncogene 1998; 17 Reviews: 1331-1342.
11. Hazell GG, et al,. G protein-coupled receptors in the hypothalamic paraventricular and supraoptic nuclei-serpentine gateways to neuroendocrine homeostasis. Front Neuroendocrinol 2011; 33: 45-66.
12. Lents NH, et al,. The rapid activation of N-Ras by alpha-thrombin in fibroblasts is mediated by the specific G-protein Galphai2-Gbeta1-Ggamma5 and occurs in lipid rafts. Cell Signal 2009; 21: 1007-1014.
13. Neves SR, et al,. G protein pathways. Science 2002; 296: 1636-1639.
14. Shraga-Levine Z, Sokolovsky M,. Functional coupling of G proteins to endothelin receptors is ligand and receptor subtype specific. Cell Mol Neurobiol 2000; 20: 305-317.
15. Lefkowitz RJ, Shenoy SK,. Transduction of receptor signals by beta-arrestins. Science 2005; 308: 512-517.
16. Pyne NJ, Pyne S,. Receptor tyrosine kinase-G-protein-coupled receptor signalling platforms: out of the shadow? Trends Pharmacol Sci 2011; 32: 443-450.
17. Yang W, et al,. Role of clathrin-mediated endocytosis in CXCR2 sequestration, resensitization, and signal transduction. J Biol Chem 1999; 274: 11328-11333.
18. Jalink K, Moolenaar WH,. G protein-coupled receptors: the inside story. Bioessays 2010; 32: 13-16.
19. Nishizuka Y,. Studies and perspectives of protein kinase C. Science 233; 4761: 305-312.
20. Butcher RW, et al,. Adenosine 3',5'-monophosphate in biological materials. II. The measurement of adenosine 3',5'-monophosphate in tissues and the role of the cyclic nucleotide in the lipolytic response of fat to epinephrine. J Biol Chem 1965; 240: 4515-4523.
21. Toward TJ, et al,. Effect of phosphodiesterase-5 inhibitor, sildenafil (Viagra), in animal models of airways disease. Am J Respir Crit Care Med 2004; 169: 227-234.
22. Seasholtz TM, et al,. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res 1999; 84: 1186-1193.
23. Vanhaesebroeck B, Waterfield MD,. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 1999; 253: 239-254.
24. Cantrell DA,. Phosphoinositide 3-kinase signalling pathways. J Cell Sci 2001; 114: 1439-1445.
25. Oudit GY, et al,. The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 2004; 37: 449-471.
26. Sata M, et al,. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8: 403-409.
27. Daub H, et al,. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors. Nature 1996; 379: 557-560.
28. Daub H, et al,. Signal characteristics of G protein-transactivated EGF receptor. EMBO J 1997; 16: 7032-7044.
29. Andresen BT, et al,. Role of EGFR transactivation in angiotensin II signaling to extracellular regulated kinase in preglomerular smooth muscle cells. Hypertension 2003; 41: 781-786.
30. Hua H, et al,. Endothelin-1 activates mesangial cell ERK1/2 via EGF-receptor transactivation and caveolin-1 interaction. Am J Physiol Renal Physiol 2003; 284: F303-F312.
31. Kanda Y, et al,. Thrombin-induced p38 mitogen-activated protein kinase activation is mediated by epidermal growth factor receptor transactivation pathway. Br J Pharmacol 2001; 132: 1657-1664.
32. Saito Y, Berk BC,. Transactivation: a novel signaling pathway from angiotensin II to tyrosine kinase receptors. J Mol Cell Cardiol 2001; 33: 3-7.
33. Vacca F, et al,. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res 2000; 60: 5310-5317.
34. Zahradka P, et al,. IGF-1 receptor transactivation mediates Src-dependent cortactin phosphorylation in response to angiotensin II. Can J Physiol Pharmacol 2009; 87: 805-812.
35. Lopez-Ilasaca M, et al,. Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase gamma. Science 1997; 275: 394-397.
36. 2+/ calmodulin-dependent transactivation of epidermal growth factor receptor. Circ Res 1998; 82: 1338-1348.
37. Wang D, et al,. Distinct effects of N-acetylcysteine and nitric oxide on angiotensin II-induced epidermal growth factor receptor phosphorylation and intracellular Ca(2+) levels. J Biol Chem 2000; 275: 12223-12230.
38. Frank GD, Eguchi S,. Activation of tyrosine kinases by reactive oxygen species in vascular smooth muscle cells: significance and involvement of EGF receptor transactivation by angiotensin II. Antioxid Redox Signal 2003; 5: 771-780.
39. Kalmes A, et al,. EGFR transactivation in the regulation of SMC function. Ann N Y Acad Sci 2001; 947: 42-55.
40. Patel HH, et al,. G-protein-coupled receptor-signaling components in membrane raft and caveolae microdomains. Handb Exp Pharmacol 2008; 186: 167-184.
41. Ushio-Fukai M, et al,. Cholesterol depletion inhibits epidermal growth factor receptor transactivation by angiotensin II in vascular smooth muscle cells: role of cholesterol-rich microdomains and focal adhesions in angiotensin II signaling. J Biol Chem 2001; 276: 48269-48275.
42. Little PJ, et al,. The paradigm of G protein receptor transactivation: a mechanistic definition and novel example. ScientificWorldJournal 2011; 11: 709-714.
43. Burch ML, et al,. TGF-beta stimulates biglycan synthesis via p38 and ERK phosphorylation of the linker region of Smad2. Cell Mol Life Sci 2010; 67: 2077-2090.
44. Burch ML, et al,. Thrombin stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by protease-activated receptor-1 transactivation of the transforming growth factor beta type I receptor. J Biol Chem 2010; 285: 26798-26805.
45. Derynck R, Zhang YE,. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425: 577-584.
46. Ebner R, et al,. Determination of type I receptor specificity by the type II receptors for TGF-beta or activin. Science 1993; 262: 900-902.
47. Massague J, et al,. Smad transcription factors. Genes Dev 2005; 19: 2783-2810.
48. Zhang Y, Derynck R,. Regulation of Smad signalling by protein associations and signalling crosstalk. Trends Cell Biol 1999; 9: 274-279.
49. Zhang S, et al,. TGFβ-induced activation of ATM and p53 mediates apoptosis in a Smad7-dependent manner. Cell Cycle 2006; 5: 2787-2795.
50. Little PJ, et al,. Endothelin-1 stimulation of proteoglycan synthesis in vascular smooth muscle is mediated by endothelin receptor transactivation of the transforming growth factor-[β] type I receptor. J Cardiovasc Pharmacol 2010; 56: 360-368.
51. Dadlani H, et al,. Smad and p38 MAP kinase-mediated signaling of proteoglycan synthesis in vascular smooth muscle. J Biol Chem 2008; 283: 7844-7852.
52. Coughlin SR,. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-264.
53. Ivey ME, Little PJ,. Thrombin regulates vascular smooth muscle cell proteoglycan synthesis via PAR-1 and multiple downstream signalling pathways. Thromb Res 2008; 123: 288-297.
54. Survase S, et al,. Actions of calcium channel blockers on vascular proteoglycan synthesis: relationship to atherosclerosis. Vasc Health Risk Manag 2005; 1: 199-208.
55. Jenkins RG, et al,. Ligation of protease-activated receptor 1 enhances α(v)β6 integrin-dependent TGF-beta activation and promotes acute lung injury. J Clin Invest 2006; 116: 1606-1614.
56. Xu MY, et al,. Lysophosphatidic acid induces αvβ6 integrin-mediated TGF-β activation via the LPA2 receptor and the small G protein G α(q). Am J Pathol 2009; 174: 1264-1279.
57. Liu Y, et al,. Serotonin induces Rho/ROCK-dependent activation of Smads 1/5/8 in pulmonary artery smooth muscle cells. FASEB J 2009; 23: 2299-2306.
58. Liu IM, et al,. TGFβ-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFβ switch. EMBO J 2009; 28: 88-98.
59. Gavras H, et al,. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med 1978; 298: 991-995.
60. Sleight P, et al,. Blood-pressure reduction and cardiovascular risk in HOPE study. Lancet 2001; 358: 2130-2131.
61. Teo K, et al,. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148: 52-61.
62. Healey JS, et al,. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45: 1832-1839.
63. Suzuki H, et al,. Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 2008; 52: 501-506.
64. Parving HH, Rossing P,. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2001; 24: 177-180.
65. Huang F, et al,. Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development. J Lipid Res 2008; 49: 521-530.
66. Chrysant SG, Chrysant GS,. The pleiotropic effects of angiotensin receptor blockers. J Clin Hypertens (Greenwich) 2006; 8: 261-268.
67. Jain MK, Ridker PM,. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005; 4: 977-987.
68. Nigro J, et al,. Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells. Atherosclerosis 2002; 162: 119-129.
69. Tannock L, et al,. Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced binding to LDL. J Lipid Res 2002; 43: 149-157.
70. Prenzel N, et al,. EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 1999; 402: 884-888.
71. Shah BH, et al,. Differential pathways of angiotensin II-induced extracellularly regulated kinase 1/2 phosphorylation in specific cell types: role of heparin-binding epidermal growth factor. Mol Endocrinol 2004; 18: 2035-2048.
72. Lee MK, et al,. TGF-β activates Erk MAP kinase signalling through direct phosphorylation of ShcA. EMBO J 2007; 26: 3957-3967.
73. Duncia JV, et al,. The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist. Med Res Rev 1992; 12: 149-191.
74. O'Donoghue ML, et al,. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of thrombin-acute coronary syndromes trial. Circulation 2011; 123: 1843-1853.
75. Angiolillo DJ, Capranzano P,. Pharmacology of emerging novel platelet inhibitors. Am Heart J 2008; 156 (Suppl. 2): S10-S15.